DexCom, Inc. - Common Stock (DXCM)

Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.

The company's bookings grew more than 20% for the second straight quarter, and the book-to-bill ratio exceeded one.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 13%. This drawdown was worse than the S&P 500’s 5.5% decline.

Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market.

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.

U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally.

U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.

Medical device company DexCom (NASDAQ:DXCM) will be reporting results tomorrow after market hours. Here’s what to look for.

Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced trade tariffs on April 2.

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Markets have tumbled in 2025, but three funds launched this year have the potential to outshine even longer-established ETFs.

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.